Role of testosterone in SARS-CoV-2 infection : A key pathogenic factor and a biomarker for severe pneumonia
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: To investigate the association between sex hormones and the severity of coronavirus disease 2019 (COVID-19). Furthermore, associations between sex hormones and systemic inflammation markers, viral shedding and length of hospital stay were studied.
DESIGN AND METHODS: This case-control study included a total of 48 male patients with COVID-19 admitted to an Italian reference hospital. The 24 cases were patients with PaO2/FiO2 <250 mmHg and who needed ventilatory support during hospitalization (severe COVID-19). The 24 controls were selected in a 1:1 ratio, matched by age, from patients who maintained PaO2/FiO2 >300 mmHg at all times and who may have required low-flow oxygen supplementation during hospitalization (mild COVID-19). For each group, sex hormones were evaluated on hospital admission.
RESULTS: Patients with severe COVID-19 (cases) had a significantly lower testosterone level compared with patients with mild COVID-19 (controls). Median total testosterone (TT) was 1.4 ng/mL in cases and 3.5 ng/mL in controls (P = 0.005); median bioavailable testosterone (BioT) was 0.49 and 1.21 in cases and controls, respectively (P = 0.008); and median calculated free testosterone (cFT) was 0.029 ng/mL and 0.058 ng/mL in cases and controls, respectively (P = 0.015). Low TT, low cFT and low BioT were correlated with hyperinflammatory syndrome (P = 0.018, P = 0.048 and P = 0.020, respectively) and associated with longer length of hospital stay (P = 0.052, P = 0.041 and P = 0.023, respectively). No association was found between sex hormone level and duration of viral shedding, or between sex hormone level and mortality rate.
CONCLUSIONS: A low level of testosterone was found to be a marker of clinical severity of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 108(2021) vom: 15. Juli, Seite 244-251 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Camici, Marta [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3XMK78S47O |
|---|
| Anmerkungen: |
Date Completed 19.08.2021 Date Revised 19.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2021.05.042 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325728100 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325728100 | ||
| 003 | DE-627 | ||
| 005 | 20231225193043.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2021.05.042 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1085.xml |
| 035 | |a (DE-627)NLM325728100 | ||
| 035 | |a (NLM)34023492 | ||
| 035 | |a (PII)S1201-9712(21)00444-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Camici, Marta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of testosterone in SARS-CoV-2 infection |b A key pathogenic factor and a biomarker for severe pneumonia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.08.2021 | ||
| 500 | |a Date Revised 19.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: To investigate the association between sex hormones and the severity of coronavirus disease 2019 (COVID-19). Furthermore, associations between sex hormones and systemic inflammation markers, viral shedding and length of hospital stay were studied | ||
| 520 | |a DESIGN AND METHODS: This case-control study included a total of 48 male patients with COVID-19 admitted to an Italian reference hospital. The 24 cases were patients with PaO2/FiO2 <250 mmHg and who needed ventilatory support during hospitalization (severe COVID-19). The 24 controls were selected in a 1:1 ratio, matched by age, from patients who maintained PaO2/FiO2 >300 mmHg at all times and who may have required low-flow oxygen supplementation during hospitalization (mild COVID-19). For each group, sex hormones were evaluated on hospital admission | ||
| 520 | |a RESULTS: Patients with severe COVID-19 (cases) had a significantly lower testosterone level compared with patients with mild COVID-19 (controls). Median total testosterone (TT) was 1.4 ng/mL in cases and 3.5 ng/mL in controls (P = 0.005); median bioavailable testosterone (BioT) was 0.49 and 1.21 in cases and controls, respectively (P = 0.008); and median calculated free testosterone (cFT) was 0.029 ng/mL and 0.058 ng/mL in cases and controls, respectively (P = 0.015). Low TT, low cFT and low BioT were correlated with hyperinflammatory syndrome (P = 0.018, P = 0.048 and P = 0.020, respectively) and associated with longer length of hospital stay (P = 0.052, P = 0.041 and P = 0.023, respectively). No association was found between sex hormone level and duration of viral shedding, or between sex hormone level and mortality rate | ||
| 520 | |a CONCLUSIONS: A low level of testosterone was found to be a marker of clinical severity of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Androgen sensitivity | |
| 650 | 4 | |a Gender imbalance | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Severity markers | |
| 650 | 4 | |a Sex hormones | |
| 650 | 4 | |a Testosterone | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Virulence Factors |2 NLM | |
| 650 | 7 | |a Testosterone |2 NLM | |
| 650 | 7 | |a 3XMK78S47O |2 NLM | |
| 700 | 1 | |a Zuppi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzini, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Scarnecchia, Liliana |e verfasserin |4 aut | |
| 700 | 1 | |a Pinnetti, Carmela |e verfasserin |4 aut | |
| 700 | 1 | |a Cicalini, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Nicastri, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Petrosillo, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Palmieri, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a D'Offizi, Gianpiero |e verfasserin |4 aut | |
| 700 | 1 | |a Marchioni, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Gagliardini, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Baldelli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Schininà, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Pianura, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Di Stefano, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Curcio, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Ciavarella, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Ippolito, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Girardi, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Vaia, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Antinori, Andrea |e verfasserin |4 aut | |
| 700 | 0 | |a ReCoVeRi Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 108(2021) vom: 15. Juli, Seite 244-251 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2021 |g day:15 |g month:07 |g pages:244-251 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2021.05.042 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2021 |b 15 |c 07 |h 244-251 | ||